Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

GSK-2646264

Alternative Names: gsk-2646264, gsk2646264, gsk 2646264
Clinical Status: Inactive
Latest Update: 2022-02-09
Latest Update Note: News Article

Product Description

GSK2646264 is a skin permeable Syk inhibitor that is being investigated as a topical treatment for skin inflammation

Mechanisms of Action: JAK2 Inhibitor,SYK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Urticaria|Lupus Erythematosus, Systemic|Lupus Erythematosus, Cutaneous

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
NCT02927457

P1

Completed

Lupus Erythematosus, Systemic|Lupus Erythematosus, Cutaneous

2018-06-12

18%

2019-03-21

Treatments
NCT02424799

P1

Completed

Urticaria

2017-11-10

2019-03-20

Treatments

Recent News Events

Date

Type

Title

02/09/2022

News Article

 Spleen Tyrosine Kinase (SYK) Inhibitors Drug Pipeline Market Report 2022 with Insights from Genosco, Portola Pharma, GSK, FUJIFILM, TopiVert, Takeda Oncology, & Asana BioSciences - ResearchAndMarkets.com

12/01/2021

PubMed

 Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study.

11/01/2021

PubMed

 Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study.

02/05/2021

News Article

 Global Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight Report 2020 Featuring Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM, TopiVert, Takeda Oncology & Asana BioSciences - ResearchAndMarkets.com

10/01/2020

PubMed

 Current and emerging treatments for chronic spontaneous urticaria.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions